From obesity to liver cancer: Can we prevent the worst?
(Universit é de Gen è ve) Hepatocellular carcinoma, a liver cancer linked to the presence of fat in the liver, is one of the leading causes of cancer death worldwide. Scientists (UNIGE) have discovered a protein involved in the progression of a " fatty liver " towards cancer. This protein could allow early detection of the risk of developing liver cancer and open the way to new targeted therapies. These results highlight the close links between our diet and cancer development. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 19, 2020 Category: Cancer & Oncology Source Type: news

Hepatocellular Carcinoma: 5 Things to Know Hepatocellular Carcinoma: 5 Things to Know
Get up to speed on the latest data surrounding the most common form of liver cancer.Medscape Gastroenterology (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 14, 2020 Category: Surgery Tags: Gastroenterology Commentary Source Type: news

China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Media News - February 14, 2020 Category: Pharmaceuticals Source Type: news

China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Investor Update - February 14, 2020 Category: Pharmaceuticals Source Type: news

Patient-Reported Outcomes Show Newer Drug Combinations Maintain Quality of Life Longer Than Current Standard-of-Care Treatments
Multiple studies showed improved patient outcomes and increased quality of life (QOL) among various treatments that previously demonstrated clinical benefits. These patient-centric findings, along with a promising new combination therapy for patients with advanced hepatocellular carcinoma (HCC) highlight some of the latest research to come out of the 2020 Gastrointestinal Cancers Symposium, held January 23-25, in San Francisco, California. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

Many Patients With NAFLD Should Be Screened for Liver Cancer, Experts Say Many Patients With NAFLD Should Be Screened for Liver Cancer, Experts Say
Screening and surveillance for hepatocellular carcinoma (HCC) is important in many patients with nonalcoholic fatty liver disease (NAFLD), according to an expert panel of the American Gastroenterological Association (AGA).Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - February 11, 2020 Category: Pathology Tags: Gastroenterology News Source Type: news

Roche to present new data on Tecentriq in combination with Avastin that shows improvement in overall survival for Chinese patients with the most common form of liver cancer
Basel, 7 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that additional data will be presented from a cohort of Chinese patients in the Phase III IMbrave150 study that evaluated Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. Data from 194 Chinese patients who took part in the IMbrave150 study were consistent with the global results, that showed a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free...
Source: Roche Investor Update - February 7, 2020 Category: Pharmaceuticals Source Type: news

Nonalcoholic Liver Disease'an Epidemic of the 21st Century'Nonalcoholic Liver Disease'an Epidemic of the 21st Century '
Can trigger a cascade of reactions, leading to liver cirrhosis, hepatocellular carcinoma, and liver failure, explains an expert.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - February 5, 2020 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news

Liver Transplant for Hepatocellular Carcinoma in the U.S. Liver Transplant for Hepatocellular Carcinoma in the U.S.
How have the patterns and outcomes for HCC-related liver transplants evolved over the last thirty years? A new study examines the trends.American Journal of Transplantation (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 3, 2020 Category: Surgery Tags: Transplantation Journal Article Source Type: news

Immunitor publishes interim results from Phase III trial of oral...
The Immunitor study is published in January issue of Hepatoma Research (ClinicalTrials.gov Identifier: NCT02232490).(PRWeb February 01, 2020)Read the full story at https://www.prweb.com/releases/immunitor_publishes_interim_results_from_phase_iii_trial_of_oral_immunotherapy_for_liver_cancer/prweb16874458.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 1, 2020 Category: Pharmaceuticals Source Type: news

QoL Extended With Atezolizumab & #43; Bevacizumab in Liver Cancer
WEDNESDAY, Jan. 29, 2020 -- For patients with unresectable hepatocellular carcinoma, the combination of atezolizumab and bevacizumab is associated with longer time to deterioration of patient-reported quality of life (QOL); and decline in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 29, 2020 Category: Pharmaceuticals Source Type: news

Effectiveness of DAA Treatment for HCV in Patients With HCC Effectiveness of DAA Treatment for HCV in Patients With HCC
Is virologic reponse to direct-acting antivirals as robust in HCV patients with hepatocellular carcinoma as in those without?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 29, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

New Therapeutic Interventions for Advanced HCC New Therapeutic Interventions for Advanced HCC
This article reviews the latest clinical trials on current and emerging first-line and second-line therapeutic options available for patients with advanced hepatocellular carcinoma.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 27, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

New Drug Combo Potentially Practice Changing in Advanced HCC New Drug Combo Potentially Practice Changing in Advanced HCC
Atezolizumab plus bevacizumab was superior to sorafenib for maintaining quality of life in patients with unresectable hepatocellular carcinoma (HCC).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 27, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
      ·Application is being reviewed under FDA ’s Real-Time Oncology Review pilot programmeBasel, 27 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectab le hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, wh...
Source: Roche Investor Update - January 27, 2020 Category: Pharmaceuticals Source Type: news

Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
Roche today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Media News)
Source: Roche Media News - January 27, 2020 Category: Pharmaceuticals Source Type: news

Genentech Submits sBLA for Atezolizumab Plus Bevacizumab Combo to Treat Unresectable HCC
The company ’s application is based on results from the phase III IMbrave150 study of the regimen for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - January 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Lower Hepatoma Risk With Earlier ALT Normalization During HBV Treatment Lower Hepatoma Risk With Earlier ALT Normalization During HBV Treatment
Earlier normalization of alanine aminotransferase (ALT) levels during treatment of chronic hepatitis B is independently associated with a reduced risk of hepatocellular carcinoma (HCC), researchers from South Korea report.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - January 21, 2020 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news

Imfinzi and tremelimumab granted Orphan Drug Designation in the US for liver cancer
AstraZeneca's Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted Orphan Drug Designation (ODD) in the US for the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer. (Source: World Pharma News)
Source: World Pharma News - January 20, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
SHANGHAI, Jan 6, 2020 -- (Healthcare Sales & Marketing Network) -- CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, today announced appointment of Yong Fan, MD, as Senior Vice Pr... Biopharmaceuticals, Oncology, Personnel CARsgen Therapeutics, T cell, CAR-T, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 6, 2020 Category: Pharmaceuticals Source Type: news

Surgical Resection vs RFA for Very Early-stage HCC Surgical Resection vs RFA for Very Early-stage HCC
This analysis compared surgical resection to radiofrequency ablation as the first-line treatment for very early-stage hepatocellular carcinoma. Which option produced best recurrence-free survival?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 17, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

No Survival Difference Between Re-Resection, Percutaneous RFA in Recurrent HCC No Survival Difference Between Re-Resection, Percutaneous RFA in Recurrent HCC
In patients with early-stage recurrent hepatocellular carcinoma (HCC), long-term survival does not differ between repeat hepatectomy and percutaneous radiofrequency ablation (RFA), a randomized trial in China suggests.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 10, 2019 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Modern TCM shows promise against liver cancer metastasis
(Natural News) Liver cancer is one of the deadliest types of human cancer. Hepatocellular carcinoma (HCC), which often occurs in patients with already existing liver disease, is considered the most common form of liver cancer. One of the main characteristics of HCC is its tendency to migrate or metastasize to the lungs. Metastasis of cancer... (Source: NaturalNews.com)
Source: NaturalNews.com - December 2, 2019 Category: Consumer Health News Source Type: news

Improved Survival Seen in Hepatoma Patients After HCV Cure Improved Survival Seen in Hepatoma Patients After HCV Cure
Cure of hepatitis C virus (HCV) infection with direct-acting antivirals is associated with increased survival in patients with HCV-related hepatocellular carcinoma (HCC), researchers report.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - November 29, 2019 Category: Transplant Surgery Tags: Gastroenterology News Source Type: news

Roche presents pivotal data demonstrating Tecentriq in combination with Avastin improves overall survival in people with the most common form of liver cancer
Roche will today present positive results from the Phase III IMbrave150 study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab). The data show statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Media News)
Source: Roche Media News - November 22, 2019 Category: Pharmaceuticals Source Type: news

Roche presents pivotal data demonstrating Tecentriq in combination with Avastin improves overall survival in people with the most common form of liver cancer
Roche will today present positive results from the Phase III IMbrave150 study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab). The data show statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - November 22, 2019 Category: Pharmaceuticals Source Type: news

Combination of immunotherapy and VEGF inhibitor improves survival in HCC
(European Society for Medical Oncology) Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC) compared to standard of care, showed results from a phase 3 study to be reported at the ESMO Asia 2019 Congress. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 22, 2019 Category: Cancer & Oncology Source Type: news

FDA Grants Priority Review to Opdivo-Yervoy Combo in Advanced HCC
The FDA has accepted the supplemental biologics license application and granted breakthrough therapy designation to nivolumab plus ipilimumab for the treatment of patients with advanced hepatocellular carcinoma previously treated with sorafenib. (Source: CancerNetwork)
Source: CancerNetwork - November 11, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Patients With Cirrhosis Have Considerable Financial Burden
FRIDAY, Nov. 8, 2019 -- The considerable financial burden of cirrhosis medical care is associated with lower surveillance for hepatocellular carcinoma (HCC), according to a study presented at The Liver Meeting, the annual meeting of the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 8, 2019 Category: Pharmaceuticals Source Type: news

Liver Steatosis Predicts Poor Outcomes in Chronic HCV Liver Steatosis Predicts Poor Outcomes in Chronic HCV
A new study finds that the presence of liver steatosis may be a risk factor for all-cause mortality and hepatocellular carcinoma among chronic hepatitis C patients.Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 6, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Characteristics, Trends of HCC in Patients Without Cirrhosis Characteristics, Trends of HCC in Patients Without Cirrhosis
This study aimed to describe the frequency and characteristics of non-cirrhotic hepatocellular carcinoma. What contribution does NAFLD make to the burden of non-cirrhotic HCC?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 30, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC)
PHILADELPHIA, Oct. 28, 2019 -- (Healthcare Sales & Marketing Network) -- SFA Therapeutics, Inc. announced today that FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company's novel human-microbiome-based treatment for human hepato... Biopharmaceuticals, Oncology, FDA SFA Therapeutics, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 28, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma
Roche today announced that the Phase III IMbrave150 study, evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, met both of its co-primary endpoints demonstrating statistically significant and clinically meaningful improvements i n overall survival (OS) and progression-free survival (PFS) compared with standard-of-care sorafenib. (Source: Roche Media News)
Source: Roche Media News - October 21, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma
Roche today announced that the Phase III IMbrave150 study, evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, met both of its co-primary endpoints demonstrating statistically significant and clinically meaningful improvements i n overall survival (OS) and progression-free survival (PFS) compared with standard-of-care sorafenib. (Source: Roche Investor Update)
Source: Roche Investor Update - October 21, 2019 Category: Pharmaceuticals Source Type: news

First-line Immunotherapy Still Elusive in Advanced Liver Cancer First-line Immunotherapy Still Elusive in Advanced Liver Cancer
First-line immunotherapy remains elusive for patients with hepatocellular carcinoma (HCC), but early results look good for a combination with bevacizumab.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 28, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche ’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma
Roche will today present results from a Phase Ib study evaluating the efficacy and safety of Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer, who have not received prior systemic therapy. (Source: Roche Media News)
Source: Roche Media News - September 27, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma
Roche will today present results from a Phase Ib study evaluating the efficacy and safety of Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer, who have not received prior systemic therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - September 27, 2019 Category: Pharmaceuticals Source Type: news

Can Sorafenib be Topped in Advanced Hepatocellular Carcinoma?
New trial results examine whether there's a drug superior to sorafenib when it comes to treating kidney cancer. (Source: CancerNetwork)
Source: CancerNetwork - September 25, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Japanese herb found to protect against liver cancer
(Natural News) Primary liver cancer is a malignant tumor that starts in the liver. The main type of primary liver cancer affecting adults is hepatocellular carcinoma (HCC). HCC starts in the hepatocytes (hepatoma) which is the liver’s main cell type. High mortality and morbidity rates are associated with HCC, which is primarily caused by uncontrolled... (Source: NaturalNews.com)
Source: NaturalNews.com - September 11, 2019 Category: Consumer Health News Source Type: news

Laboratory for Advanced Medicine Receives FDA Breakthrough Device Designation for Liquid Biopsy Liver Cancer Detection Test
The blood-based liquid biopsy test analyzes the DNA methylation pattern of cell-free DNA (cfDNA) indicating the presence of hepatocellular carcinoma as early as Stage I IRVINE, Calif., Sept. 3, 2019 -- (Healthcare Sales & Marketing Network) -- Laborato... Diagnostics, Oncology, FDA Laboratory for Advanced Medicine, Liver Cancer, Liquid Biopsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 3, 2019 Category: Pharmaceuticals Source Type: news

HCC and DAA Treatment in Decompensated Cirrhosis HCC and DAA Treatment in Decompensated Cirrhosis
This review explores controversies surrounding the potential impact of DAA therapy on the incidence and prognosis of hepatocellular carcinoma in patients with advanced liver disease.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Mixed Outcomes After Liver Resection for NAFLD-Associated Cancer Mixed Outcomes After Liver Resection for NAFLD-Associated Cancer
Liver resection for nonalcoholic fatty liver disease (NAFLD)-associated hepatocellular carcinoma (HCC) is associated with favorable long-term survival but with more surgical morbidity and post-hepatectomy liver failure, compared with non-NAFLD HCC, researchers from Singapore report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 28, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

DAAs Cut Deaths in Those Treated for HCV-Related Liver Cancer
TUESDAY, Aug. 20, 2019 -- Among patients with hepatitis C virus (HCV) infection and complete response to hepatocellular carcinoma (HCC) treatment, direct-acting antiviral (DAA) therapy is associated with a significant reduction in the risk for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 20, 2019 Category: Pharmaceuticals Source Type: news

Lipophilic Statins May Cut Liver Cancer in Chronic Viral Hepatitis
TUESDAY, Aug. 20, 2019 -- Lipophilic statin use is associated with significantly reduced hepatocellular carcinoma (HCC) incidence and mortality in adults with chronic viral hepatitis, according to a study published online Aug. 20 in the Annals of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 20, 2019 Category: Pharmaceuticals Source Type: news

Aspirin May Improve Liver Function After Embolization of HCC
MONDAY, Aug. 12, 2019 -- Aspirin therapy can improve liver function and survival in patients who have received chemoembolization or transarterial embolization for hepatocellular carcinoma, according to a study published in the September issue of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 12, 2019 Category: Pharmaceuticals Source Type: news

Neoadjuvant Radiotherapy Beneficial in Resectable Liver Cancer With Portal Vein Tumor Thrombus Neoadjuvant Radiotherapy Beneficial in Resectable Liver Cancer With Portal Vein Tumor Thrombus
Neoadjuvant three-dimensional conformal radiotherapy (RT) followed by hepatectomy boosts outcomes over those with hepatectomy alone in patients with resectable hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT), researchers from China report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 3, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Recommendations for Personalised HCC Treatment With Y90 TheraSphere(TM) Published by an International Multidisciplinary Group
Supported by comparative Dosisphere data, a phase II multicentric randomised dosimetry trial LONDON, July 23, 2019 -- (Healthcare Sales & Marketing Network) -- BTG plc (LSE: BTG), a global healthcare company, today announced consensus recommendations f... Devices, Interventional, Oncology BTG, TheraSphere, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 23, 2019 Category: Pharmaceuticals Source Type: news

New biomarker-guided strategy has potential for liver cancer treatment
(University of Texas M. D. Anderson Cancer Center) A study at The University of Texas MD Anderson Cancer Center discovered a cellular pathway tied to cancer that may be beneficial in reducing side effects and extending duration of immunotherapy in some patients with hepatocellular carcinoma, the most common form of liver cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 15, 2019 Category: Cancer & Oncology Source Type: news

Diabetes and Risk of HCC and Mortality in Chronic HBV Diabetes and Risk of HCC and Mortality in Chronic HBV
This study investigated the impact of diabetes mellitus on the development and prognosis of hepatocellular carcinoma in individuals with chronic hepatitis B virus infection.Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 2, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Treatment With DAAs for HCV and Risk of HCC Treatment With DAAs for HCV and Risk of HCC
This study indicates that the risk of hepatocellular carcinoma remains high in HCV patients with advanced fibrosis, even after achieving viral eradication with DAAs.Liver International (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - June 28, 2019 Category: Pathology Tags: Gastroenterology Journal Article Source Type: news